Vericel Co. (NASDAQ:VCEL) Stock Position Raised by International Assets Investment Management LLC

International Assets Investment Management LLC lifted its position in Vericel Co. (NASDAQ:VCEL) by 4,126.7% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 634 shares of the biotechnology company’s stock after buying an additional 619 shares during the quarter. International Assets Investment Management LLC’s holdings in Vericel were worth $27,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in VCEL. OLD National Bancorp IN grew its position in Vericel by 23.3% in the third quarter. OLD National Bancorp IN now owns 5,513 shares of the biotechnology company’s stock worth $233,000 after acquiring an additional 1,043 shares in the last quarter. Creative Planning acquired a new stake in shares of Vericel in the 3rd quarter valued at $230,000. Valeo Financial Advisors LLC bought a new stake in Vericel in the third quarter worth $387,000. Juncture Wealth Strategies LLC increased its position in Vericel by 48.1% during the third quarter. Juncture Wealth Strategies LLC now owns 11,643 shares of the biotechnology company’s stock worth $492,000 after buying an additional 3,783 shares during the last quarter. Finally, Handelsbanken Fonder AB increased its position in Vericel by 24.0% during the third quarter. Handelsbanken Fonder AB now owns 15,479 shares of the biotechnology company’s stock worth $654,000 after buying an additional 3,000 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on VCEL. StockNews.com upgraded Vericel from a “sell” rating to a “hold” rating in a research note on Friday. Stephens upped their target price on Vericel from $56.00 to $58.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Truist Financial increased their price target on Vericel from $56.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday, July 16th. BTIG Research reduced their price objective on shares of Vericel from $56.00 to $55.00 and set a “buy” rating for the company in a research note on Monday, July 15th. Finally, Canaccord Genuity Group assumed coverage on shares of Vericel in a research note on Friday, August 9th. They issued a “buy” rating and a $57.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $57.71.

Vericel Trading Up 7.9 %

Shares of Vericel stock opened at $54.00 on Friday. Vericel Co. has a 1 year low of $32.28 and a 1 year high of $54.47. The company’s fifty day simple moving average is $44.27 and its 200-day simple moving average is $46.40. The company has a market cap of $2.65 billion, a price-to-earnings ratio of 900.00 and a beta of 1.66.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.03. Vericel had a net margin of 0.37% and a return on equity of 0.35%. The firm had revenue of $57.91 million during the quarter, compared to the consensus estimate of $55.32 million. As a group, research analysts forecast that Vericel Co. will post 0.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Vericel news, Director Steven C. Gilman sold 5,833 shares of the company’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $41.36, for a total value of $241,252.88. Following the completion of the transaction, the director now owns 11,000 shares of the company’s stock, valued at $454,960. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Vericel news, Director Steven C. Gilman sold 5,833 shares of Vericel stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $41.36, for a total transaction of $241,252.88. Following the sale, the director now owns 11,000 shares in the company, valued at $454,960. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Dominick Colangelo sold 17,500 shares of the business’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $41.38, for a total transaction of $724,150.00. Following the completion of the sale, the chief executive officer now directly owns 220,937 shares in the company, valued at $9,142,373.06. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 29,166 shares of company stock valued at $1,200,764 over the last three months. 5.20% of the stock is owned by corporate insiders.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.